跳至主要内容
临床试验/ACTRN12621001656820
ACTRN12621001656820招募中未知

Exploring the Impact of Sex Hormones and Obesity on Asthma Outcomes in Women with Asthma

The University of Newcastle0 个研究点目标入组 150 人开始时间: 2021年12月1日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
入组人数
150

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 o limit(—)
性别
Female

入选标准

  • 1.Physician diagnosed asthma
  • 2.Female >=18 years of age
  • 3.Confirmed variable airflow obstruction at screening visit or documented within the past 10 years:
  • Bronchodilator response >200mL OR >12% (post-bronchodilator FEV1 following administration of 400µg salbutamol, pMDI with spacer; after 10 minutes, or following administration of nebulised Ventolin)
  • Airway hyperresponsiveness (in response to any standard challenge agent)
  • Peak flow variability >12% when monitored over at least one week
  • FEV1 variability >12% (between two FEV1 values measured within two months of each other)
  • If not observed at screening visit or documented in file, then provide peak flow meter for two weeks monitoring, if required.
  • 4.Using a combined monophasic oral contraceptive pill (Groups 3 and 4 only).
  • 5.Stable disease with no respiratory infection, asthma exacerbation, corticosteroid burst (>10mg/day) or use of antibiotics to treat an asthma exacerbation, or change in asthma therapy in the four weeks preceding visit 1.
  • 6.Able to provide written informed consent

排除标准

  • 1.Asthma is not the primary respiratory diagnosis
  • 2.Treatment with oral corticosteroids in the preceding four weeks (unless a low dose is being taken on a long-term basis: >=10mg for >3 months)
  • 3.Current smoker, or smoked in the last six months
  • 4.Perimenopausal (menstrual cycle less frequent or irregular with symptoms of estrogen insufficiency)
  • 5.Pregnancy or breastfeeding
  • 6.Endocrine disorder resulting in amenorrhoea (e.g. thyroid disease, hyper-prolactinoma or known pituitary disorder)
  • 7.Irregular menstrual cycle (variability >15 days between shortest and longest cycle over 12 months or cycle length outside the range of 26-34 days)
  • 8.Hormonal contraceptive use (other than the combined monophasic oral contraceptive pill for Groups 3 and 4)
  • 9.Current lung cancer or other blood, lymphatic or solid organ malignancy
  • 10.NSAID burst within 48 hours of study visit
  • 11.Participant has a clinically important medical illness (including serious psychological disorders) likely to interfere with management or participation in the study

研究者

相似试验

Exploring the Impact of Sex Hormones and Obesity on... | 临床试验